Brief: Nuvation Bio Reports Q4 And Full Year 2022 Financial Results And Provides Business Update

Nuvation Bio

15/03/2023 20:08

March 15 (Reuters) - Nuvation Bio Inc  NUVB.N :
    * NUVATION BIO REPORTS FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
    * INITIATED BOTH DOSING REGIMENS OF PHASE 1B STUDY OF
NUV-868 IN
COMBINATION WITH OLAPARIB OR ENZALUTAMIDE
    * DOSING ONGOING FOR PHASE 1 MONOTHERAPY STUDY OF NUV-868
    * NOMINATED UNDISCLOSED DRUG-DRUG CONJUGATE (DDC) AS FIRST
CLINICAL CANDIDATE; EXPECT TO SUBMIT AN IND BY YEAR END 2023
    * STRONG BALANCE SHEET WITH CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES OF $661.0 MILLION AS OF DECEMBER 31, 2022
    * QTRLY LOSS PER SHARE $0.10
    * Q4 EARNINGS PER SHARE VIEW $-0.12 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBwcyNT9a 
Further company coverage:  NUVB.N 

 ((Reuters.Briefs@thomsonreuters.com;))